Список проголосовавших за комментарий " Vertex Pharma upgraded to Buy at Maxim Group after tez/iva data; tgt $143 (107.29)Maxim Group upgrades VRTX to Buy from Hold and sets target price at $143 after positive data from two pivotal studies of tezacaftor/ivacaftor (tez/iva) in F508del homozygotes (EVOLVE) and in the first of two studies in heterozygotes (EXPAND, F508del/residual CFTR). Firm is pleasantly surprised to see how well the combination worked in particular in the heterozygote population...and it worked better than Orkambi in homozygotes, too. Tez/iva is now the new backbone of the CF franchise. <strong>Given the positive data in both the EVOLVE and EXPAND studies, firm believes the probability of success in the remaining heterozygote P3 study (data 2H17), as well as the four triple combination studies with tez/iva as the backbone, is skewed in favor of Vertex. They also now see reduced risk in the long term Vertex story and believe the company is in fact realizing their vision to create a foundation from which to dominate the CF landscape for years to come.</strong>"